Shares of OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $3.42.
Several equities analysts recently commented on the company. UBS Group set a $4.00 price objective on OPKO Health in a research note on Friday, October 16th. Zacks Research downgraded OPKO Health from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 6th. Piper Sandler restated an "overweight" rating and issued a $4.00 target price (up from $3.00) on shares of OPKO Health in a research note on Friday, October 16th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of OPKO Health in a research report on Wednesday, November 11th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of OPKO Health in a research report on Friday, October 16th.
Check Out Our Latest Report on OPKO Health
Institutional Trading of OPKO Health
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC bought a new stake in shares of OPKO Health during the 3rd quarter worth $245,000. Aquatic Capital Management LLC bought a new position in OPKO Health in the third quarter valued at $168,000. Goldman Sachs Group Inc. raised its position in OPKO Health by 13.8% during the third quarter. Goldman Sachs Group Inc. now owns 8,005,331 shares of the biotechnology company's stock valued at $12,889,000 after purchasing an additional 969,839 shares in the last quarter. Kovack Advisors Inc. raised its position in OPKO Health by 96.8% during the third quarter. Kovack Advisors Inc. now owns 1,055,404 shares of the biotechnology company's stock valued at $1,699,000 after purchasing an additional 519,202 shares in the last quarter. Finally, Caxton Associates LLP bought a new stake in OPKO Health during the third quarter worth about $452,000. Institutional investors own 64.63% of the company's stock.
OPKO Health Price Performance
Shares of NASDAQ OPK opened at $1.57 on Friday. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -8.26 and a beta of 1.52. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.65 and a current ratio of 4.97. OPKO Health has a fifty-two week low of $0.98 and a fifty-two week high of $1.86. The firm's 50-day simple moving average is $1.61 and its 200 day simple moving average is $1.37.
OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). OPKO Health had a negative return on equity of 10.90% and a negative net margin of 29.51%. The business had revenue of $130.83 million for the quarter, compared to analysts' expectations of $136.62 million. During the same period last year, the business earned $0.03 EPS. The business's revenue was down 56.9% on a year-over-year basis. As a group, research analysts anticipate that OPKO Health will post -0.20 earnings per share for the current fiscal year.
About OPKO Health
(
Get Free Report)
OPKO Health is a healthcare company with businesses in diagnostics and pharmaceuticals. Its diagnostic offerings have included BioReference Health laboratory services and the 4Kscore test, which helps assess the risk of aggressive prostate cancer. OPKO's pharmaceutical products include Rayaldee, a prescription treatment for certain adults with chronic kidney disease and vitamin D insufficiency. The company also co-developed NGENLA, a long-acting growth hormone treatment for children with growth hormone deficiency, with Pfizer.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OPKO Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OPKO Health wasn't on the list.
While OPKO Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.